西黄胶囊辅助治疗转移性结直肠癌的疗效及对免疫功能的影响  

Efficacy of Xihuang capsules as an adjuvant treatment for metastatic colorectal cancer and its impact on immune function

作　　者：翁桢泓[1] 罗玮[2] 李丽琳 孔庆豪 罗建华[2] 谢应槟 蔡康余 陈筱婷[4] WENG Zhenhong;LUO Wei;LI Lilin;KONG Qinghao;LUO Jianhua;XIE Yingbin;CAI Kangyu;CHEN Xiaoting(Department of Gastrointestinal Surgery,Cancer Hospital of Shantou University Medical College,Shantou 515000;Department of Oncology,The People’s Hospital of Guangning,Guangning 526300;Department of Radiotherapy,Zhujiang Hospital,Southern Medical University,Guangzhou 510282,China;Department of Oncology,Zhujiang Hospital,Southern Medical University,Guangzhou 510282,China)

机构地区：[1]汕头大学医学院附属肿瘤医院胃肠外科,广东汕头515000 [2]广宁县人民医院肿瘤科,广东广宁526300 [3]南方医科大学珠江医院放疗科,广东广州510282 [4]南方医科大学珠江医院肿瘤科,广东广州510282

出　　处：《细胞与分子免疫学杂志》2024年第11期1005-1010,共6页Chinese Journal of Cellular and Molecular Immunology

基　　金：北京科创医学发展基金(KC2023-JX-0186-FQ042)。

摘　　要：目的探讨西黄胶囊辅助治疗转移性结直肠癌的有效性与安全性及对免疫功能的影响。方法回顾性分析112例转移性结直肠癌患者的临床资料,根据是否服用西黄胶囊将患者分为对照组(56例)和观察组(56例),对两组患者的疗效、生活质量改善情况、毒副作用及免疫功能等进行分析比较。结果治疗后,观察组在疾病控制率(DCR)和生活质量改善率方面均显著超越对照组,而癌胚抗原(CEA)水平及骨髓抑制、肝肾功能损害等不良事件的发生率则明显低于对照组;治疗后观察组患者外周血CD4^(+)、CD8^(+)T细胞百分比、CD8^(+)/CD4^(+)T细胞及血清高迁移率族蛋白B1(HMGB1)、白细胞介素2(IL-2)水平较治疗前均显著升高;亚组分析发现基线生存质量评分(KPS)≤80、CD8^(+)/CD4^(+)T细胞比值高及HMGB1含量高的患者在观察组中的客观缓解率(ORR)显著升高,而KPS≤80、CD8^(+)/CD4^(+)T细胞比值低及CEA、IL-2含量高的IVB期患者在观察组中具有更显著的DCR。结论西黄胶囊辅助治疗对晚期结直肠癌具有显著的临床效果,有助于提升患者的生活质量,减轻化疗毒副作用,改善患者免疫功能状态,尤其是对于肿瘤负荷较大的患者获益更为显著,值得临床推广应用。Objective To investigate the efficacy and safety of Xihuang capsules as an adjuvant treatment for metastatic colorectal cancer and their impact on immune function.Methods A retrospective analysis was conducted on clinical data from 112 patients diagnosed with metastatic colorectal cancer.The patients were categorized into two groups:a control group(n=56)that did not take Xihuang capsules and an observation group(n=56)that did.The efficacy,improvement of quality of life,toxic and side effects and immune function of the two groups were analyzed and compared.Results After treatment,the disease control rate(DCR)and the rate of improvement in quality of life were significantly higher in the observation group compared to the control group.Additionally,levels of carcinoembryonic antigen(CEA)and the incidence of adverse reactions,including bone marrow suppression and liver and kidney function damage,were significantly lower in the observation group.Furthermore,the percentages of CD4^(+)and CD8^(+)T cells,the CD8^(+)/CD4^(+)T cells ratio,as well as serum levels of high mobility group box-1(HMGB1)and interleukin 2(IL-2)in observation group were significantly elevated compared to pre-treatment levels.Subgroup analysis revealed that patients with a Karnofsky Performance Status(KPS)score≤80,a high CD8^(+)/CD4^(+)T cells ratio,and elevated HMGB1 levels experienced a significantly higher objective response rate(ORR)in the observation group.Conversely,patients with stage IVB disease,who had KPS score≤80,a low CD8^(+)/CD4^(+)T cells ratio and high CEA and IL-2 levels demonstrated a more pronounced DCR in the observation group.Conclusion Xihuang capsules exhibit promising clinical efficacy as an adjuvant treatment for advanced colorectal cancer.They not only enhance patients’quality of life and reduce the toxic and adverse effects of chemotherapy,but also improve immune function.These benefits are particularly significant in patients with a high tumor burden,indicating that Xihuang capsules are worthy of clinical application

关 键 词：西黄胶囊 转移性结直肠癌 免疫功能 有效性 

分 类 号：S853.53[农业科学—临床兽医学] R574.62[农业科学—兽医学] R967[农业科学—畜牧兽医] R283[医药卫生—消化系统]